Trials / Completed
CompletedNCT01262911
Effect of SRT2379 on Endotoxin-Induced Inflammation
A Phase I Study to Evaluate a Single Oral Dose of SRT2379 on the Endotoxin Induced Inflammatory Response in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Sirtris, a GSK Company · Industry
- Sex
- Male
- Age
- 18 Years – 35 Years
- Healthy volunteers
- Accepted
Summary
SRT2379 is a potent small molecule activator of SIRT1 that has been found to inhibit systemic inflammation induced by intravenous injection of lipopolysaccharide (LPS) in mice. The objective of this study is to test if SRT2379 may be a novel compound for the treatment of inflammatory disorders in man.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SRT2379 | SRT2379 will be supplied as hard gelatin capsules, with each containing 250mg. |
| DRUG | Placebo | Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo. |
Timeline
- Start date
- 2011-02-17
- Primary completion
- 2011-04-26
- Completion
- 2011-04-26
- First posted
- 2010-12-17
- Last updated
- 2017-08-04
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT01262911. Inclusion in this directory is not an endorsement.